Health and Human Services Secretary Robert F. Kennedy Jr. announced the revocation of emergency use authorizations (EUAs) for COVID-19 vaccines, marking a significant shift in vaccine policy. RFK Jr. outlined four commitments he stated were fulfilled: ensuring vaccines remain available for those who desire them, particularly vulnerable populations; demanding placebo-controlled trials from pharmaceutical companies; and transitioning to full FDA approval for specific groups.

The decision effectively ends the use of EUAs for COVID-19 vaccines across the general public, a measure previously used to justify widespread mandates during the Biden administration. The FDA now grants marketing authorization for higher-risk individuals, including Moderna’s vaccine for those 6 months and older, Pfizer’s for 5 years and older, and Novavax for 12 years and older. These vaccines remain accessible to patients who choose them after consulting with healthcare providers.

RFK Jr. emphasized that the move aligns with public demands for “science, safety, and common sense.” However, critics on social media argued the action falls short of addressing harms linked to the vaccines. Meanwhile, rumors persist about potential restrictions under a future administration, though no official announcements have been made.

The American Academy of Pediatrics (AAP) expressed concern over the decision, with President Susan Kressly calling it “deeply troubling.” She warned that barriers to vaccination could endanger children during respiratory virus season, as young infants and toddlers face heightened risks from respiratory illnesses.

While doctors can still prescribe vaccines off-label for individuals outside FDA-approved age ranges, this creates additional hurdles for public access, particularly for those relying on pharmacies rather than physician consultations. The Centers for Disease Control and Prevention’s vaccine advisory committee is expected to review the policy, though RFK Jr.’s recent replacement of all 17 panel members with his own appointments raises questions about impartiality.

The changes may also affect insurance coverage for individuals who do not qualify for the updated vaccine recommendations.